Influence of Genetic Variants in Type I Interferon Genes on Melanoma Survival and Therapy

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Lenci, Romina Elizabeth ^a   Bevier, Melanie ^a   Brandt, Andreas ^a   Bermejo, Justo Lorenzo ^b   Sucker, Antje ^c   Moll, Iris ^c   Planelles, Dolores ^d   Requena, Celia ^d   Nagore, Eduardo ^d   Hemminki, Kari ^a   Schadendorf, Dirk ^c   Kumar, Rajiv ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERFERON;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADJUVANT THERAPY; ADULT; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHROMOSOME 9P; DISEASE FREE SURVIVAL; FEMALE; GENE; GENE CLUSTER; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IFNW1 GENE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; SPAIN;

ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INTERFERON TYPE I; INTERFERONS; MALE; MELANOMA; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 84870284054     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050692     Document Type: Article

References (40)

1. Zeuthen J, Dzhandzhugazyan K, Hansen MR, Kirkin AF, (1998) The immunogenic properties of human melanomas and melanoma-associated antigens recognized by cytotoxic T lymphocytes. Bratisl Lek Listy 99: 426-434.
2. Kirkin AF, Dzhandzhugazyan K, Zeuthen J, (1998) Melanoma-associated antigens recognized by cytotoxic T lymphocytes. APMIS 106: 665-679.
3. Kirkin AF, Dzhandzhugazyan K, Zeuthen J, (1998) The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes. Exp Clin Immunogenet 15: 19-32.
4. Barnetson RS, Halliday GM, (1997) Regression in skin tumours: a common phenomenon. Australas J Dermatol 38 (Suppl 1): S63-65.
5. Kiniwa Y, Fujita T, Akada M, Ito K, Shofuda T, et al. (2001) Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma. Cancer Res 61: 7900-7907.
6. Stoff B, Salisbury C, Parker D, O'Reilly Zwald F, (2010) Dermatopathology of skin cancer in solid organ transplant recipients. Transplant Rev (Orlando) 24: 172-189.
7. Gajewski TF, (2007) Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 13: 5256-5261.
8. Rass K, Hassel JC, (2009) Chemotherapeutics, chemoresistance and the management of melanoma. G Ital Dermatol Venereol 144: 61-78.
9. Sznol M, (2011) Molecular markers of response to treatment for melanoma. Cancer J 17: 127-133.
10. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM, (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16: 5-24.
11. Kahler KC, Egberts F, Hauschild A (2010) [Current aspects of adjuvant therapy of malignant melanoma]. Hautarzt 61: 523-531; quiz 532-523.
12. Simons DL, Lee G, Kirkwood JM, Lee PP, (2011) Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med 9: 52.
13. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, et al. (2000) High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18: 2444-2458.
14. Mohr P, Weichenthal M, Hauschild A, (2003) Adjuvant therapy in melanoma. Onkologie 26: 227-233.
15. Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, et al. (2005) Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366: 1189-1196.
16. Yang XR, Liang X, Pfeiffer RM, Wheeler W, Maeder D, et al. (2010) Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations. Fam Cancer 9: 625-633.
17. Wieczorek S, Dahmen N, Kasten M, Epplen JT, Gencik M, (2004) A rare form of narcolepsy (HLA-DR2-) shows possible association with (functionally relevant) alpha-interferon gene polymorphisms. Psychiatr Genet 14: 47-51.
18. Akahoshi M, Ishihara M, Remus N, Uno K, Miyake K, et al. (2004) Association between IFNA genotype and the risk of sarcoidosis. Hum Genet 114: 503-509.
19. Kim JW, Roh JW, Park NH, Song YS, Kang SB, et al. (2003) Interferon, alpha 17 (IFNA17) Ile184Arg polymorphism and cervical cancer risk. Cancer Lett 189: 183-188.
20. Hirankarn N, Tangwattanachuleeporn M, Wongpiyabovorn J, Wongchinsri J, Avihingsanon Y, (2008) Genetic association of interferon-alpha subtypes 1, 2 and 5 in systemic lupus erythematosus. Tissue Antigens 72: 588-592.
21. Janssen R, Bont L, Siezen CL, Hodemaekers HM, Ermers MJ, et al. (2007) Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J Infect Dis 196: 826-834.
22. Sini MC, Manca A, Cossu A, Budroni M, Botti G, et al. (2008) Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma. Br J Dermatol 158: 243-250.
23. Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B, (2010) Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression. PLoS Genet 6: e1000899.
24. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E, (2007) The role of site accessibility in microRNA target recognition. Nat Genet 39: 1278-1284.
25. Bao L, Zhou M, Wu L, Lu L, Goldowitz D, et al. (2007) PolymiRTS Database: linking polymorphisms in microRNA target sites with complex traits. Nucleic Acids Res 35: D51-54.
26. Sethupathy P, Collins FS, (2008) MicroRNA target site polymorphisms and human disease. Trends Genet 24: 489-497.
27. John B, Enright AJ, Aravin A, Tuschl T, Sander C, et al. (2004) Human MicroRNA targets. PLoS Biol 2: e363.
28. Betel D, Wilson M, Gabow A, Marks DS, Sander C, (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res 36: D149-153.
29. Schug J (2008) Using TESS to predict transcription factor binding sites in DNA sequence. Curr Protoc Bioinformatics Chapter 2: Unit 2 6.
30. Rakosy Z, Vizkeleti L, Ecsedi S, Begany A, Emri G, et al. (2008) Characterization of 9p21 copy number alterations in human melanoma by fluorescence in situ hybridization. Cancer Genet Cytogenet 182: 116-121.
31. Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, et al. (2009) Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 41: 920-925.
32. Falchi M, Bataille V, Hayward NK, Duffy DL, Bishop JA, et al. (2009) Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet 41: 915-919.
33. Chatzinasiou F, Lill CM, Kypreou K, Stefanaki I, Nicolaou V, et al. (2011) Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. J Natl Cancer Inst 103: 1227-1235.
34. Olopade OI, Jenkins RB, Ransom DT, Malik K, Pomykala H, et al. (1992) Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res 52: 2523-2529.
35. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, et al. (2011) 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature 470: 264-268.
36. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, et al. (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354: 709-718.
37. Mellman I, Coukos G, Dranoff G, (2011) Cancer immunotherapy comes of age. Nature 480: 480-489.
38. Alexandrescu DT, Ichim TE, Riordan NH, Marincola FM, Di Nardo A, et al. (2010) Immunotherapy for melanoma: current status and perspectives. J Immunother 33: 570-590.
39. Petrella T, Verma S, Spithoff K, Quirt I, McCready D (2012) Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review and Practice Guideline. Clin Oncol (R Coll Radiol).
40. Larkin JM, Fisher RA, Gore ME (2012) Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review. Clin Oncol (R Coll Radiol).